Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Non Operating Income came in at -$3.5 million in Q1 2026, down 247.61% year-on-year from $2.4 million in Q1 2025, and down 475.3% quarter-over-quarter from $931000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non Operating Income history runs 10 years deep, the most recent figure standing at -$3.5 million for Q1 2026.
- On a quarterly basis, Non Operating Income fell 247.61% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was $845000.0, a 87.12% decrease from a year earlier, with the FY2025 full-year figure at $6.7 million, up 16.42% from the prior year.
- Non Operating Income retreated to -$3.5 million in Q1 2026 per SRRK's latest filing, from $931000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $2.9 million in Q4 2024 and bottomed at -$3.5 million in Q1 2026.
- The 5-year median for Non Operating Income is $1.2 million (2023), against an average of $843882.4.
- Across the five-year window, Non Operating Income surged 341.86% in 2025 and tumbled 247.61% in 2026, its largest moves.
- Year by year, Non Operating Income stood at $1.2 million in 2022, then jumped by 62.49% to $1.9 million in 2023, then surged by 52.31% to $2.9 million in 2024, then tumbled by 67.93% to $931000.0 in 2025, then slumped by 475.3% to -$3.5 million in 2026.
- Per Business Quant, the three latest SRRK Non Operating Income figures stand at -$3.5 million (Q1 2026), $931000.0 (Q4 2025), and $1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.49 Mn |
| Dec 31, 2025 | 931,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 301,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 565,000.00 |
| Jun 30, 2022 | -853,000.00 |
| Mar 31, 2022 | -1.02 Mn |
| Dec 31, 2021 | -550,000.00 |
| Sep 30, 2021 | -430,000.00 |
| Jun 30, 2021 | -434,000.00 |